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Background: Although the superiority of the new generation drug-eluting stents (DES) everolimus-eluting stents (EES) compared to paclitaxel-
eluting stents (PES) has been established in some randomized trials, the advantages of EES over PES in the setting of acute myocardial infarction 
(AMI) remains unclear.
Methods: A total of 2911 AMI patients who underwent percutaneous coronary intervention (PCI) with PES (n=1210), or EES (n=1701) were enrolled 
from Korea Acute Myocardial Infarction Registry (KAMIR). The composite clinical outcomes at 1 year were compared between the 2 groups. Target 
lesion failure (TLF) was defined as the composite of cardiac death, target lesion recurrent nonfatal myocardial infarction (Re-MI), or target lesion 
revascularization (TLR). Total major adverse cardiac events (MACE) included total death, Re-MI, and target vessel revascularization (TVR).
Results: The two groups had well matched baseline characteristics. The clinical outcomes at 1 year showed that the incidences of cardiac death 
and total death were comparable between the 2 groups. However, EES group had significantly lower incidences of Re-MI (1.4% vs 2.7%, P=0.008), 
TLR (1.2% vs 3.1%, P<0.001), TVR (1.6% vs 4.3%, P<0.001), TLF (6.1% vs 10.2%, P<0.001), total MACE (8.2% vs 13.4%, P<0.001), and stent 
thrombosis (0.4% vs 1.8%, P<0.001) as compared with PES group. After multivariable Cox regression adjusted for baseline confounders, the use of 
EES was still independently associated with lower incidences of Re-MI [odds ratio (OR) 0.44, 95% confidence interval (CI) 0.24-0.79, P=0.006], TLR 
(OR 0.34, 95% CI 0.19-0.62, P<0.001), TVR (OR 0.35, 95% CI 0.21-0.57, P<0.001), TLF (OR 0.59, 95% CI 0.44-0.79, P<0.001), total MACE (OR 0.59, 
95% CI 0.46-0.76, P<0.001), and stent thrombosis (OR 0.12, 95% CI 0.04-0.37, P<0.001) as compared with PES.
Conclusions: Despite similar 1-year mortality, the present study suggests that the use of EES in AMI is superior to PES in reducing stent thrombosis 
and other major individual end points at 1 year.
